BUDGET IMPACT ANALYSIS OF APREMILAST IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS IN GREECE
Author(s)
Solakidi A1, Tzanetakos C2, Kourlaba G1, Batsi M3, Vostitsanou Z3, Maniadakis N4
1EVROSTON LP, Athens, Greece, 2Evroston LP, Athens, Greece, 3Genesis pharma, Athens, Greece, 4National School οf Public Health, Athens, Greece
OBJECTIVES: To assess the budget impact of increased use of apremilast, in the current treatment portfolio available for the management of adult patients with active psoriatic arthritis (PsA) who have failed to respond to, or are intolerant to, conventional disease-modifying antirheumatic drugs (DMARDs) from a Greek payer perspective. METHODS: A 5-year (2018-2022) budget impact model was developed to estimate healthcare costs for adults with active PsA. Target population was defined based on epidemiological data, obtained from local experts and the literature. The population was divided into three categories; patients receiving conventional DMARDs eligible to receive treatment with biologics or apremilast, patients currently treated with biologics or apremilast (switchers), and newly diagnosed patients eligible to receive treatment with biologics or apremilast (incidents). The analysis included all relevant currently reimbursed biologics (adalimumab, etanercept, golimumab, infliximab, ustekinumab, secukinumab, certolizumab pegol) and apremilast. Biosimilars for etanercept and infliximab were also included in the model. Reported IMS (2017) prescription data were used for building up the market shares of alternative therapies. Market penetration of apremilast was assumed to increase on average by 4% from 2018 to 2022. Following a payer perspective, direct costs relating to drug acquisition and administration were considered (€, 2018). RESULTS: A total of 5,569 patients were estimated to receive biologics or apremilast in the first model year. Increased penetration of apremilast resulted at an estimated decrease in the total budget by 16.5%, leading to cost-savings of €€€ CONCLUSIONS: Increased use of apremilast for the treatment of active PsA represents a cost-saving strategy in the Greek healthcare setting.
Conference/Value in Health Info
2018-11, ISPOR Europe 2018, Barcelona, Spain
Value in Health, Vol. 21, S3 (October 2018)
Code
PSS13
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Sensory System Disorders